CIK 0001662579 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 35.9 M | 20.8 M | 31.1 M | |
| Net income (USD) | -128.2 M | -83.9 M | ||
| Diluted EPS (USD/shares) | -1.27 | -2.67 | -2.62 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-02 | 4 | FORM 4 | 2026-10-01 |
| 2026-10-02 | 4 | FORM 4 | 2026-10-01 |
| 2026-09-25 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-25 |
| 2026-09-21 | 4 | FORM 4 | 2026-09-18 |
| 2026-08-14 | 144 | 144 | |
| 2026-08-14 | 144 | 144 | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-13 | 144 | 144 | |
| 2026-08-12 | 144 | 144 | |
| 2026-08-12 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-11 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-11 | 8-K | 8-K items 2.02,9.01 | 2026-08-11 |
| 2026-07-27 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-07-13 | 4 | FORM 4 | 2026-07-10 |
| 2026-07-02 | 4 | FORM 4 | 2026-07-01 |
| 2026-07-02 | 4 | FORM 4 | 2026-07-01 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
| 2026-06-26 | 4 | FORM 4 | 2026-06-24 |
Forms on file (last 1,000): 4 260, 8-K 75, 3 27, SC 13G/A 22, SC 13G 19, 10-Q 18, SCHEDULE 13G/A 17, 144 9. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=CCCC (0.002 USD), /gw/filings/filings?ticker=CCCC&form=8-K, /gw/filings/facts?ticker=CCCC&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange